Roche terminated cooperation with domestic diagnostic companies in order to adjust its strategic layout

Recently, there have been reports that Roche, its holding company Foundation Medicine (FMI) and its Chinese partner Dean Diagnostics have jointly decided to terminate the existing cooperation
.
In this regard, the industry believes that the decision means that the original partners will not be able to carry out genome analysis and testing work through the previous business model
.
According to public information, Dean Diagnostics was established in 2001 and is a third-party medical diagnostic service organization with the provision of diagnostic service outsourcing as its core business
.
In April 2018, Roche announced that Roche and its holding company, FoundationMedicine, Inc.
, have signed a cooperation agreement with Dean Diagnostics Group Co.
, Ltd.
to jointly promote the process of individualized cancer diagnosis and treatment in China
.
According to the relevant agreement, Dean Diagnostics will become the exclusive partner of FMI's comprehensive tumor genome sequencing analysis service (CGP) in the Chinese clinical market, launching advanced genome sequencing service products, establishing a Dean tumor precision diagnostic laboratory, and building a standardized full process Quality management system, to realize the application of FMI's FoundationOne, FoundationOneHeme and FoundationACT products in China (except Macau, Hong Kong and Taiwan), to find suitable treatment options for cancer patients
.
Regarding the termination of the cooperation, Roche Pharmaceuticals stated that the decision was made based on the overall consideration of the effectiveness of the existing operating model and business development
.
It is worth noting that since this year, Roche has acted frequently in the domestic market
.
Roche has previously stated that it will add a new Chinese product pipeline strategy team
.
At the same time, Ms.
Chen Xingrong, the head of the company's transformation and innovation office, will concurrently serve as the head of the China product pipeline strategy team
.
According to Roche Pharmaceuticals, the establishment of the Chinese product pipeline strategy team is mainly to strengthen China's overall strategic layout, and to work closely with headquarters and all parties in the industry chain to benefit more patients in China
.
The industry believes that in recent years, as Roche has continuously increased its attention to the Chinese market, it has been acting frequently in order to maintain continuous development in the Chinese market.

.
At present, it is not uncommon to strengthen cooperation with domestic enterprises and adjust personnel structure
.
For example, in terms of cooperation with domestic companies, Cinda Biotech announced on June 9 that Innovent Biologics (HK) Limited, a wholly-owned subsidiary of the company, has reached a strategic cooperation agreement with Roche Group.
The two parties mainly focus on research, clinical development and business.
Develop a number of bispecific antibodies and cell therapy products, which will be directly used in the treatment of hematological tumors and solid tumors
.
In addition, in terms of internal structure adjustment, it is reported that since this year, in addition to Ms.
Chen Xingrong, the head of the Office of Transformation and Innovation, also serves as the head of the Chinese product pipeline strategy team.
In July, Roche also issued an announcement stating that Roche Pharmaceuticals China is currently News that Bian Xin, vice president of market access, will take over the job of President Zhou Hong, who will leave on September 30, as the president of Roche Pharmaceuticals China
.
The industry believes that with the normalization of pharmaceutical policies such as volume procurement, foreign pharmaceutical companies will be under increasing pressure.
In order to cope with this situation, it is expected that many pharmaceutical companies will also choose to conduct domestic business in the future.
Structural adjustments
.